| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED SEPTEMBER 2021. Refer to TA740: Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | apalutamide (Erleada®) | |
| Formulation | 60 mg tablet | |
| Reference number | 2450 | |
| Indication | For the treatment of non-metastatic castration-resistant prostate cancer (NM CRPC) who are at high risk of developing metastatic disease |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Date of issue | 14/05/2019 | |
| NICE guidance | ||